Close Menu

Trovagene

Trovagene said this week that Charles Cantor has joined the company's scientific advisory board.

Trovagene has launched a noninvasive next-gen sequencing-based test that assesses seven known mutations in the KRAS gene.

Trovagene has appointed Charles Cantor to its scientific advisory board. Cantor is a professor emeritus of biomedical engineering and of pharmacology and was the director of the Center for Advanced Biotechnology at Boston University.

NEW YORK (GenomeWeb News) – Trovagene today announced a partnership with Catholic Health Initiatives Center for Translational Research (CTR) to evaluate the effectiveness of Trovagene's cell-free DNA cancer monitoring diagnostics in clinical practice.

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market on Monday a 71 percent drop in revenues for its fourth quarter.

Trovagene said this week that Rodney Markin has joined the company's board of directors.

David Flannery, a pediatric geneticist, is the new medical director of the American College of Medical Genetics and Genomics.

Cornell Research Foundation has been awarded

NEW YORK (GenomeWeb News) – Trovagene and US Oncology Research today announced a deal for the use of Trovagene's technology to determine whether KRAS mutations can be evaluated in urine to monitor pancreatic cancer patients.

NEW YORK (GenomeWeb News) – Trovagene reported after the close of the market Thursday that its third quarter revenues fell to $44,000 from $211,000 year over year.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.